



# UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/623,922	08/31/2001	Vassilios Papadopoulos	1941.017US1	9599
21186	7590	01/25/2007	EXAMINER	
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. BOX 2938 MINNEAPOLIS, MN 55402			DANG, IAN D	
		ART UNIT	PAPER NUMBER	
				1647
SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
30 DAYS	01/25/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO. <b>09/623,922</b>	FILING DATE <b>08/31/2001</b>	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION <b>Vassilios, Papadopoulos</b>	ATTORNEY DOCKET NO. <b>1941.017US1</b>
--	----------------------------------	---	---

EXAMINER

Ian Dang

ART UNIT

PAPER

1647

20070118

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Applicant's election with traverse of Group I, claims 1-8 and 20 in the communication filed on 07/31/2006 has been acknowledged. In the Office action mailed on 9/21/2006, the Examiner requested a further restriction requirement to a species election. However, Applicants traversed the election of species requirement by arguing that all the species fall within the scope of SEQ ID NO:26 and the species for the cholesterol recognition/interaction amino acid sequences all have structural relationship. Although species for the cholesterol recognition/interaction amino acid sequences are structurally similar, they are different from one another because each of them has a different sequence from one another. Thus each species is patentably distinct.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The species of disease are as follows:

SEQ ID NO: X, number 1-23 corresponding to SEQ ID NO:1 to SEQ ID NO:23 (disclosed on page 10 and in Table 1 on page 12)

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner: 1.

The following claim(s) are generic: claims 1-8, and 20.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the species encoded by SEQ ID NO:1 in claim 1 have different amino sequences from one another.

BRIDGET BUANNER  
PATENT EXAMINER

Ian Dang  
Patent Examiner  
Art Unit 1647  
January 19, 2007